High cardiovascular morbidity and mortality remains a persisting problem in patients with CKDPCSK9 inhibition represents a novel and successful treatment approach to reduce LDL-C in patients with normal to moderately impaired kidney function. As the authors of a review published today in NDT [1] conclude, specific studies in chronic kidney disease patients are mandatory to prove the efficacy and safety of PCSK9 inhibitors and to determine their ability to improve outcomes in these patients.
Source: EurekaAlert, https://www.eurekalert.org